Zee shareholders approve appointment of Divya Karani, Saurav Adhikari to board
ADVERTISEMENT The appointments were cleared through a remote e-voting postal ballot that concluded on July 8. More than 75% of the votes cast were in favour of the appointment.
According to the company, the approvals reflect shareholders' confidence in the board's direction and its efforts to drive value creation and long-term growth. The appointments are part of a broader initiative by ZEEL to reinforce its governance framework and align Board composition with strategic priorities.
Ms. Karani brings over 30 years of experience in advertising and media, having previously served as CEO of Dentsu Media, South Asia. She currently serves as Chairperson and Executive Director at Kulfi Collective, a modern media network focused on content, commerce, and culture.Mr. Adhikari also brings more than three decades of experience in operations and investment roles across the technology, FMCG, and consumer durables sectors. His previous roles include leadership positions at HCL, Unilever, and PepsiCo. He is currently the Founder and Senior Partner at Indus Tech Edge Fund I, a growth fund focused on globalizing India's technology ecosystem.Commenting on the appointments, R. Gopalan, Chairman of ZEEL, said: 'We are grateful to the shareholders for recognising the value that Ms. Karani and Mr. Adhikari will bring to the Board. Their sharp business acumen, coupled with their creative expertise from respective sectors, will only strengthen the Board's directional guidance to the management team as the Company progresses towards the targeted aspirations. We remain committed towards fortifying the Company and maximizing shareholder value, through all our decisions.'
ADVERTISEMENT The company's board recently approved a preferential issue of convertible warrants worth up to Rs 2,237.44 crore to promoter group entities Altilis Technologies and Sunbright Mauritius Investments, raising their stake from 3.99% to 18.39%, subject to shareholder approval at a 10 July EGM via video conferencing.
(You can now subscribe to our ETMarkets WhatsApp channel)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
11 minutes ago
- Deccan Herald
Kumaraswamy must work to get funds for Karnataka: D K Shivakumar
The DCM, who also holds the water resources portfolio, said that he had appealed to the Centre to provide funds to the tune of Rs 11,122.76 crore for six irrigation projects in the state.
India.com
15 minutes ago
- India.com
India's Pharma War Zone: How Delhi's Bulk Drug Push Is Rattling China
New Delhi: The heat is rising in India's pharmaceutical backrooms. Quiet factories. Long shifts. New chemical reactors humming across Himachal, Gujarat and Telangana. Something has shifted. China, long the uncontested supplier of India's drug ingredients, is suddenly nervous. Its prices are falling. Fast. Some slashed by 50%. This is no coincidence. The trigger? India's Rs 6,940 crore Production-Linked Incentive (PLI) scheme. Launched in March 2020, it was a shot across the bow. And the target: reduce dependence on Chinese Active Pharmaceutical Ingredients (APIs). By December 2024, 48 domestic API projects were sanctioned. Of these, 34 are already operational. Together, they cover 25 key drug molecules. The investment so far? Rs 4,254 crore. But the Chinese are not backing down quietly. They are throwing prices into free fall. Landed costs of certain APIs from China have collapsed far deeper than Indian prices. Take Atorvastatin, used in cholesterol pills, for instance. Indian API prices fell 17% to Rs 10,000 per kg. China pushed it down to Rs 8,000 per kg. That is a 33% crash. Let's understand with another example of Ofloxacin, a broad-spectrum antibiotic. Indian prices dropped from Rs 3,200 to Rs 2,700. China? Rs 2,100. Down 30% in a year. This is price war, not coincidence. Bhavin Mukund Mehta, director of the Kilitch Drugs and Vice Chairman of Pharmexcil, minced no words, 'Even though the PLI has helped reduce the prices of domestically-produced APIs, the Chinese players are undercutting the competition in specific product categories to retain their market share.' Behind the scenes, policymakers are reviewing the PLI's next phase. They are asked industry insiders for help. The mission is to stop China's dumping spree, push for stronger local production and close the gaping supply chain hole exposed during COVID. The Department of Pharmaceuticals is now asking – can India stand on its own chemical legs and can it stop the bleed from Beijing's pricing games? The pressure is on. China still supplies around 70% of India's API imports. India imports about 50% of its total bulk drug needs. That is the strategic choke point the PLI is aiming to break. The scheme covers the production period from FY23 to FY29. But the impact is already being felt. Jatish Sheth, secretary general of the Confederation of Indian Pharmaceutical Industry, sees this as China's last stand. 'It is an expected move from the Chinese exporters to bring down the bulk drugs prices. While their focus is to retain the market share, we believe that this is a temporary phenomenon. We do not expect the Chinese players to keep selling the drugs at such low prices for too long.' He is betting on patience. Indian drugmakers are playing the long game. With new infrastructure, newer molecules and tighter government support, the tide could soon turn. But for now, it is a staring contest across lab benches and import docks. On one side, old Chinese dominance. On the other, rising Indian ambition backed by billions. And in between? A market worth tens of billions and the chemical backbone of the world's pharmacy.
Time of India
15 minutes ago
- Time of India
Court shuts Ajmer's Rs 243 crore bridge inaugurated days ago
Ramsetu bridge suffered structural damage after the first rainfall since its construction AJMER: In a damning indictment of public infrastructure management, the Ajmer Judicial Magistrate Court Number-2 on Wednesday ordered to immediately close the newly inaugurated Ramsetu bridge that suffered structural damage last week after the first rainfall since its construction. Rajasthan's Rs 243 crore project, meant to be a symbol of urban development, now stands as a monument to alleged administrative negligence and questionable construction practices. Judge Manmohan Chandel passed the order while treating a joint suit filed by two residents as a PIL. The court has directed both the Ajmer Municipal Corporation (AMC) and the Ajmer Smart City Ltd (ASCL) to submit their responses by July 11. The suit was filed on July 5, after which court issued notices to the district collector, AMC and ASCL. None of the respondents appeared on July 8 leading to a subsequent hearing on July 9. The closure order came on Wednesday despite the corporation's assertion that it had blocked one of the four roads on the elevated stretch. The court noted that since the same material was used in the bridge's construction, the entire structure posed a safety risk. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Bogotá: IA: gana hasta $2,700 a la semana trabajando desde casa Gran oportunidad Registro Undo The court's decision came after shocking revelations that the bridge, operational for merely days, showed significant structural deterioration following the season's first heavy rainfall on July 3. More alarmingly, court proceedings revealed the project proceeded without expert consultation, and relied instead on decisions made by a local citizens' forum. The pressing question that people are now grappling with is: How did a multi-crore infrastructure project fail so spectacularly, and who will be held responsible?
